CL2016003434A1 - Método ex vivo de pronóstico de metástasis en cáncer de próstata - Google Patents

Método ex vivo de pronóstico de metástasis en cáncer de próstata

Info

Publication number
CL2016003434A1
CL2016003434A1 CL2016003434A CL2016003434A CL2016003434A1 CL 2016003434 A1 CL2016003434 A1 CL 2016003434A1 CL 2016003434 A CL2016003434 A CL 2016003434A CL 2016003434 A CL2016003434 A CL 2016003434A CL 2016003434 A1 CL2016003434 A1 CL 2016003434A1
Authority
CL
Chile
Prior art keywords
metastases
prognosis
prostate cancer
vivo method
expression
Prior art date
Application number
CL2016003434A
Other languages
English (en)
Inventor
Cerda Infante Javier
MONTECINOS ACUÑA Viviana
Original Assignee
Pontificia Univ Catolia De Chile
Cerda Infante Javier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Univ Catolia De Chile, Cerda Infante Javier filed Critical Pontificia Univ Catolia De Chile
Priority to CL2016003434A priority Critical patent/CL2016003434A1/es
Priority to ES17887687T priority patent/ES2949875T3/es
Priority to EP17887687.6A priority patent/EP3564665B1/en
Priority to PCT/CL2017/050095 priority patent/WO2018119544A1/es
Priority to US16/474,459 priority patent/US20190345563A1/en
Priority to CA3048551A priority patent/CA3048551A1/en
Publication of CL2016003434A1 publication Critical patent/CL2016003434A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

Método ex vivo de pronóstico de metástasis en cáncer de próstata que comprende determinar el nivel de expresión de al menos uno de los siguientes genes: NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 y GALNT16, en una muestra biológica que contenga células de estroma de tumor primario de cáncer de próstata; y establecer si la expresión de los genes está aumentada o disminuida, y correlacionarlo con el pronóstico de metástasis en CaP.
CL2016003434A 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata CL2016003434A1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata
ES17887687T ES2949875T3 (es) 2016-12-30 2017-12-29 Método ex vivo de pronóstico de metástasis en cáncer de próstata
EP17887687.6A EP3564665B1 (en) 2016-12-30 2017-12-29 Ex-vivo method for the prognosis of metastasis in prostate cancer
PCT/CL2017/050095 WO2018119544A1 (es) 2016-12-30 2017-12-29 Método ex vivo de pronóstico de metástasis en cáncer de próstata
US16/474,459 US20190345563A1 (en) 2016-12-30 2017-12-29 Ex-vivo method for the prognosis of metastasis in prostate cancer
CA3048551A CA3048551A1 (en) 2016-12-30 2017-12-29 Ex vivo method for the prognosis of metastasis in prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata

Publications (1)

Publication Number Publication Date
CL2016003434A1 true CL2016003434A1 (es) 2018-11-23

Family

ID=62706585

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003434A CL2016003434A1 (es) 2016-12-30 2016-12-30 Método ex vivo de pronóstico de metástasis en cáncer de próstata

Country Status (6)

Country Link
US (1) US20190345563A1 (es)
EP (1) EP3564665B1 (es)
CA (1) CA3048551A1 (es)
CL (1) CL2016003434A1 (es)
ES (1) ES2949875T3 (es)
WO (1) WO2018119544A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2008058018A2 (en) * 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2680692A1 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
EP2048242A1 (de) * 2007-10-08 2009-04-15 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Microarray für die Expressionsanalyse der zellulären Glykosylierungsmaschinerie
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2012129408A2 (en) * 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2014052930A2 (en) 2012-09-28 2014-04-03 The Regents Of The University Of California, Irvine Biomarkers for prostate cancer prognosis
EP2762574A1 (en) * 2013-01-31 2014-08-06 Fina Biotech, S.L. Non-invasive diagnostic method for diagnosing bladder cancer
EP3011050B1 (en) * 2013-06-19 2017-09-06 Memorial Sloan Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis

Also Published As

Publication number Publication date
EP3564665B1 (en) 2023-05-03
EP3564665A1 (en) 2019-11-06
US20190345563A1 (en) 2019-11-14
CA3048551A1 (en) 2018-07-05
WO2018119544A1 (es) 2018-07-05
ES2949875T3 (es) 2023-10-03
EP3564665A4 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
CL2017000752A1 (es) Procedimiento para producir biomasa que tiene un alto contenido de exopolisacáridos
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
CO2019011359A2 (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
WO2018013531A8 (en) AUTO-ANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
NZ730124A (en) A method of predicting risk of recurrence of cancer
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
CL2016003434A1 (es) Método ex vivo de pronóstico de metástasis en cáncer de próstata
DK3436568T3 (da) Kulturmedium til pluripotente stamceller
MX2019014661A (es) Variantes de b4galt1 y usos de estas.
MX2015013197A (es) Biomarcadores de la respuesta farmacodinamica tumoral.
EA201690684A1 (ru) Способ осветления выросшей клеточной массы неочищенной культуры клеток с высокой плотностью клеток